GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Return-on-Tangible-Asset

Nanoviricides (Nanoviricides) Return-on-Tangible-Asset : -60.09% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Nanoviricides's annualized Net Income for the quarter that ended in Dec. 2023 was $-8.46 Mil. Nanoviricides's average total tangible assets for the quarter that ended in Dec. 2023 was $14.08 Mil. Therefore, Nanoviricides's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -60.09%.

The historical rank and industry rank for Nanoviricides's Return-on-Tangible-Asset or its related term are showing as below:

NNVC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -73.4   Med: -35.62   Max: -5.04
Current: -56.39

During the past 13 years, Nanoviricides's highest Return-on-Tangible-Asset was -5.04%. The lowest was -73.40%. And the median was -35.62%.

NNVC's Return-on-Tangible-Asset is ranked worse than
61.95% of 1556 companies
in the Biotechnology industry
Industry Median: -40.005 vs NNVC: -56.39

Nanoviricides Return-on-Tangible-Asset Historical Data

The historical data trend for Nanoviricides's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Return-on-Tangible-Asset Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.91 -73.40 -33.00 -30.55 -43.25

Nanoviricides Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.45 -35.63 -82.05 -49.77 -60.09

Competitive Comparison of Nanoviricides's Return-on-Tangible-Asset

For the Biotechnology subindustry, Nanoviricides's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Return-on-Tangible-Asset falls into.



Nanoviricides Return-on-Tangible-Asset Calculation

Nanoviricides's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-8.589/( (23.153+16.566)/ 2 )
=-8.589/19.8595
=-43.25 %

Nanoviricides's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-8.46/( (15.085+13.073)/ 2 )
=-8.46/14.079
=-60.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Nanoviricides  (AMEX:NNVC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Nanoviricides Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (Nanoviricides) Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides (Nanoviricides) Headlines

From GuruFocus